We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00116662
First Posted: July 1, 2005
Last Update Posted: February 19, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Graceway Pharmaceuticals, LLC
June 30, 2005
July 1, 2005
February 19, 2007
March 2005
Not Provided
Clearance of treated common wart(s)
Same as current
Complete list of historical versions of study NCT00116662 on ClinicalTrials.gov Archive Site
  • Partial clearance of treated common wart(s)
  • Wart recurrence
Same as current
Not Provided
Not Provided
 
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.

A second purpose is to evaluate the safety of the drug.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Warts
Drug: Resiquimod
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of common wart(s)
  • Ages between 3 to 11

Exclusion Criteria:

  • Other types of wart(s), ie. plantar
  • Currently participating in another clinical study
  • Chronic viral hepatitis B or C
Sexes Eligible for Study: All
3 Years to 11 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00116662
1534-RESI
Not Provided
Not Provided
Not Provided
Not Provided
Graceway Pharmaceuticals, LLC
Not Provided
Not Provided
Graceway Pharmaceuticals, LLC
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP